ALNY — Alnylam Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $42.09bn
- $41.88bn
- $3.71bn
Annual balance sheet for Alnylam Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,436 | 2,192 | 2,439 | 2,695 | 2,908 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 199 | 238 | 328 | 405 | 778 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2,809 | 2,692 | 2,983 | 3,295 | 4,051 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 734 | 739 | 726 | 694 | 708 |
| Other Long Term Assets | |||||
| Total Assets | 3,643 | 3,546 | 3,830 | 4,240 | 4,966 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 696 | 768 | 968 | 1,186 | 1,466 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,055 | 3,705 | 4,051 | 4,173 | 4,177 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 588 | -158 | -221 | 67.1 | 789 |
| Total Liabilities & Shareholders' Equity | 3,643 | 3,546 | 3,830 | 4,240 | 4,966 |
| Total Common Shares Outstanding |